HealthCor Management’s Teva Pharmaceuticals TEVA Stock Holding History

HealthCor Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-499,640	Closed	-$3.76M	–	69
2022 Q2	$3.76M	Buy	+499,640	New	+$4.35M	0.38%	41
2020 Q2	–	Sell	-1,492,800	Closed	-$13.4M	–	62
2020 Q1	$13.4M	Buy	+1,492,800	New	+$15.3M	0.57%	40
2016 Q2	–	Sell	-419,760	Closed	-$22.5M	–	49
2016 Q1	$22.5M	Sell	419,760 -570,750	-58%	-$33.5M	1.27%	23
2015 Q4	$65M	Buy	+990,510	New	+$61.2M	3.95%	9
2015 Q3	–	Sell	-63,200	Closed	-$3.73M	–	57
2015 Q2	$3.73M	Sell	63,200 -1,086,800	-95%	-$67M	0.19%	44
2015 Q1	$71.6M	Buy	1,150,000 +866,000	+305%	+$50.4M	3.42%	9
2014 Q4	$16.3M	Buy	+284,000	New	+$15.8M	0.91%	34
2014 Q1	–	Sell	-165,200	Closed	-$6.62M	–	67
2013 Q4	$6.62M	Buy	+165,200	New	+$6.5M	0.4%	40

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

HealthCor Management's TEVA Position: Q3 2022 in Review

HealthCor Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 499,640 shares — an estimated $3.76M sold.

HealthCor Management first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $71.6M in Q1 2015. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

HealthCor Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
HealthCor Management sold 499,640 Teva Pharmaceuticals shares in Q3 2022, an estimated $3.76M.
HealthCor Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
HealthCor Management's Teva Pharmaceuticals position peaked at $71.6M in Q1 2015.
430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on HealthCor Management's 13F filing for Q3 2022, filed 14 Nov 2022.